Influence of Skin Subjective Symptoms on Sleep Quality in Patients with Cutaneous Disorders: A Study of 2871 Subjects.
cutaneous disorders
sleep quality
unpleasant sensations
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
11
2020
accepted:
31
12
2020
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
20
2
2021
Statut:
epublish
Résumé
Previous studies showed more sleep disturbance (SD) in patients with cutaneous disorders (CD). During CD, unpleasant subjective symptoms [USS], such as itch, pain and others (tingling, burning, or tightness) have a negative influence on sleep quality. This study aims to evaluate the prevalence of SD in CD patients and to identify the influence of itch, pain and other unpleasant sensations on SD. An international, anonymized real-life survey was conducted with individuals [18-75 years], with physician-confirmed CD, or without CD. The 25 items covered sociodemographic characteristics, feeling of overall sleep quality and skin unpleasant sensations. Severity of SD and unpleasant sensations were assessed using a 10-cm Visual Analogue Scale (VAS). From 3834 analyzed questionnaires, 2871 (67.3%) were in the CD group and 863 (32.7%) in the control group. Patients with CD had significantly more SD (71.2% vs 32.7% in the control group, p<0.0001). CD patients without any reported unpleasant sensation were at higher risk for SD than control subjects (OR 1,362 [95% CI 1.975-2.405] p=0.0013). SS were highly associated with SD (OR 1.641 [95% CI 1.393-1.933] p<0.0001). Pruritus, pain and intermediate sensations were significant predictors of SD, with odds ratios of 1.670, 1.625 and 1.326, respectively. VAS sleep scores were strongly associated with pruritus (r: 0.25, p<0.0001) and pain (r: 0.25 p<0.0001) severity ratings. SD is a common problem for patients with CD. Patients with subjective symptoms suffer more from SD, suggesting that they are aggravating factors, but are likely not the only reason for SD in CD patients. We found that during CD, intermediate sensations also contribute to SD. Despite some limitations and the potential bias due to the study design, our results confirm for the first time on an international level the influence of subjective symptoms on sleep quality in patients with CD.
Identifiants
pubmed: 33603431
doi: 10.2147/CCID.S288557
pii: 288557
pmc: PMC7886096
doi:
Types de publication
Journal Article
Langues
eng
Pagination
143-152Informations de copyright
© 2021 Halioua et al.
Déclaration de conflit d'intérêts
Bruno Halioua is a private dermatologist. V. Delvigne and S. Seité are employees of La Roche-Posay, France. Sophie Seite reports personal fees from La Roche-Posay, during the conduct of the study and outside the submitted work. Clara Chelli reports grants from Sanofi, outside the submitted work. The authors report no other potential conflicts of interest for this work.
Références
PLoS One. 2012;7(11):e51183
pubmed: 23226485
Reumatologia. 2018;56(5):301-306
pubmed: 30505012
Ann N Y Acad Sci. 2008;1129:287-304
pubmed: 18591489
Acta Derm Venereol. 2018 Aug 29;98(8):757-761
pubmed: 29756157
Am J Clin Dermatol. 2003;4(12):833-42
pubmed: 14640776
Acta Derm Venereol. 2010;90(1):39-45
pubmed: 20107724
J Clin Med. 2020 Apr 22;9(4):
pubmed: 32331207
Sleep Breath. 2019 Sep;23(3):893-898
pubmed: 30859369
Postepy Dermatol Alergol. 2019 Dec;36(6):659-666
pubmed: 31997991
Handb Clin Neurol. 2011;98:vii
pubmed: 21056174
Acta Derm Venereol. 2015 Apr;95(4):485-8
pubmed: 25365961
J Am Acad Dermatol. 2010 Jul;63(1):114-23
pubmed: 19944485
Sleep Med. 2005 Jan;6(1):5-13
pubmed: 15680289
Medicine (Baltimore). 2019 Dec;98(49):e18059
pubmed: 31804312
Inflamm Allergy Drug Targets. 2014;13(3):177-90
pubmed: 24853682
Acta Derm Venereol. 2015 Mar;95(3):312-6
pubmed: 24978135
Br J Dermatol. 2009 Mar;160(3):633-41
pubmed: 19014398
Depress Anxiety. 2003;18(4):228-32
pubmed: 14661193
Br J Dermatol. 2000 Nov;143(5):969-73
pubmed: 11069504
Arch Intern Med. 1998 May 25;158(10):1099-107
pubmed: 9605781
PLoS One. 2009;4(2):e4589
pubmed: 19240794
Int J Dermatol. 2020 Feb;59(2):159-164
pubmed: 31605395
Dermatol Ther (Heidelb). 2017 Sep;7(3):349-364
pubmed: 28707054
Psychol Med. 1978 May;8(2):325-9
pubmed: 26096
Lancet. 1999 Oct 23;354(9188):1435-9
pubmed: 10543671
J Am Soc Hypertens. 2017 Feb;11(2):122-129
pubmed: 28109722
Eur J Pain. 2006 Jul;10(5):473-8
pubmed: 16678456
J Eur Acad Dermatol Venereol. 2015 Feb;29(2):291-297
pubmed: 24754427
Acta Derm Venereol. 2019 Feb 1;99(2):175-180
pubmed: 30307027
Sleep Med Rev. 2010 Feb;14(1):69-82
pubmed: 19962922
Int J Rheum Dis. 2017 Sep;20(9):1212-1218
pubmed: 25363664
Sleep Med Rev. 2018 Oct;41:255-265
pubmed: 29759891
Int J Mol Sci. 2016 Mar 22;17(3):425
pubmed: 27011178
Ann Dermatol. 2016 Jun;28(3):321-6
pubmed: 27274630
PLoS One. 2016 Jan 08;11(1):e0146462
pubmed: 26745869
Vitam Horm. 2012;89:241-57
pubmed: 22640617
Sleep. 2018 Sep 1;41(9):
pubmed: 29955877
Sleep Med Clin. 2007;2(2):161-169
pubmed: 19098992
J Invest Dermatol. 2015 Apr;135(4):984-991
pubmed: 25521458
Sleep Med Rev. 2010 Dec;14(6):351-8
pubmed: 20188609
Br J Dermatol. 2018 Dec;179(6):1376-1384
pubmed: 29704428
Asian J Psychiatr. 2015 Oct;17:24-8
pubmed: 26277226
J Dermatol Sci. 2013 Nov;72(2):195-7
pubmed: 23876306
Sleep Med Rev. 2016 Oct;29:63-75
pubmed: 26624228
Sleep Med. 2008 Sep;9 Suppl 1:S23-8
pubmed: 18929315
Clin Dermatol. 2013 Jan-Feb;31(1):118-26
pubmed: 23245983
Int J Dermatol. 2019 Aug;58(8):976-981
pubmed: 31168791
Pflugers Arch. 2013 Dec;465(12):1671-85
pubmed: 23636773
Biomed Res Int. 2017;2017:5617838
pubmed: 28828385
Dermatitis. 2016 Mar-Apr;27(2):50-8
pubmed: 26983091
Br J Dermatol. 2019 Jun;180(6):1289-1290
pubmed: 31157426
Med Sci (Paris). 2014 Dec;30(12):1123-8
pubmed: 25537042
Acta Derm Venereol. 2011 Sep;91(5):537-40
pubmed: 21533325
Sleep Med. 2009 Apr;10(4):427-38
pubmed: 18753000
Med Hypotheses. 2010 Dec;75(6):535-7
pubmed: 20678867
Sleep Med Clin. 2017 Mar;12(1):31-38
pubmed: 28159095